<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Pires IS</submitter><funding>Howard Hughes Medical Institute</funding><funding>Foundation for the National Institutes of Health</funding><funding>Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)</funding><funding>Ragon Institute of MGH, MIT and Harvard</funding><funding>NCI NIH HHS</funding><funding>MIT | Deshpande Center for Technological Innovation, Massachusetts Institute of Technology</funding><pagination>322-334</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12867765</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>25(2)</volume><pubmed_abstract>Immunotherapies such as immune checkpoint inhibitors are effective in treating several advanced cancers, but these treatments have had limited success in metastatic ovarian cancer. Here we engineered liposomal nanoparticles carrying a poly-ʟ-arginine/poly-ʟ-glutamate coating that promotes their binding and retention on the surface of ovarian cancer cells. Covalent anchoring of the potent immunostimulatory cytokine interleukin-12 (IL-12) to phospholipid headgroups of the liposome core enabled the polymer-coated particles to concentrate IL-12 in disseminated ovarian cancer tumours following intraperitoneal administration. Shedding of the layer-by-layer coating and serum-protein-mediated extraction of IL-12-conjugated lipids from the liposomal core over time enabled IL-12 to disseminate in th</pubmed_abstract><journal>Nature materials</journal><pubmed_title>IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer.</pubmed_title><pmcid>PMC12867765</pmcid><funding_grant_id>F99CA274651</funding_grant_id><funding_grant_id>R01CA235375</funding_grant_id><funding_grant_id>F99 CA274651</funding_grant_id><funding_grant_id>P30 CA014051</funding_grant_id><funding_grant_id>R01 CA235375</funding_grant_id><pubmed_authors>Nombera Bueno E</pubmed_authors><pubmed_authors>Irvine DJ</pubmed_authors><pubmed_authors>Gomerdinger VF</pubmed_authors><pubmed_authors>Melo MB</pubmed_authors><pubmed_authors>Covarrubias G</pubmed_authors><pubmed_authors>Suh H</pubmed_authors><pubmed_authors>Pickering AJ</pubmed_authors><pubmed_authors>Billingsley MM</pubmed_authors><pubmed_authors>Backlund C</pubmed_authors><pubmed_authors>Shanker A</pubmed_authors><pubmed_authors>Wu S</pubmed_authors><pubmed_authors>Gordon E</pubmed_authors><pubmed_authors>Pires IS</pubmed_authors><pubmed_authors>Hammond PT</pubmed_authors><pubmed_authors>Pryor M</pubmed_authors></additional><is_claimable>false</is_claimable><name>IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer.</name><description>Immunotherapies such as immune checkpoint inhibitors are effective in treating several advanced cancers, but these treatments have had limited success in metastatic ovarian cancer. Here we engineered liposomal nanoparticles carrying a poly-ʟ-arginine/poly-ʟ-glutamate coating that promotes their binding and retention on the surface of ovarian cancer cells. Covalent anchoring of the potent immunostimulatory cytokine interleukin-12 (IL-12) to phospholipid headgroups of the liposome core enabled the polymer-coated particles to concentrate IL-12 in disseminated ovarian cancer tumours following intraperitoneal administration. Shedding of the layer-by-layer coating and serum-protein-mediated extraction of IL-12-conjugated lipids from the liposomal core over time enabled IL-12 to disseminate in th</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Feb</publication><modification>2026-07-15T13:23:02.29Z</modification><creation>2026-07-05T03:08:32.51Z</creation></dates><accession>S-EPMC12867765</accession><cross_references><pubmed>41174039</pubmed><doi>10.1038/s41563-025-02390-9</doi></cross_references></HashMap>